Back

Immune checkpoint inhibitors and atherosclerotic cardiovascular events: a retrospective cohort study

27 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: T-cells, checkpoint inhibitors, and cardiac complications Cardio-Oncology ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Sean Tan

Monash University, Melbourne (Australia)

7 More presentations in this session

Presentation thumbnail
Cardiovascular complications of chimeric antigen receptor (CAR)-T cell therapy
Associate Professor F. Guerra (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Atrial and ventricular arrhythmias with immune checkpoint inhibitor therapy in patients without evidence of myocarditis
Doctor J. Heemelaar (Leiderdorp, NL)
Abstract Slides Video
Presentation thumbnail
Arterial inflammation induced by immune checkpoint inhibitors assessed on 18F-FDG PET-CT scans in stage III/IV melanoma patients
Miss E. Polomski (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Gender differences in cardio-oncology care of patients treated with immune checkpoint inhibitor therapy
Associate Professor R. Mincu (Essen, DE)
Abstract Slides Video
Presentation thumbnail
Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels and reduces myocardial strain through NLRP3 and MyD-88 pathways
Doctor N. Maurea (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
T-cells, checkpoint inhibitors, and cardiac complications

The Event

Event poster

ESC Congress 2023

27 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular adverse events in primary lung cancer patients treated with immune checkpoint inhibitors: a nationwide database study
thumbnail
Congress Presentation
Immunotherapy management in active cancer patients after atherosclerosis-associated acute coronary syndromes during immune checkpoint inhibitors treatment
thumbnail
Congress Presentation
Acute myocardial infarction - a case of nivolumab-induced cardiotoxicity

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources